Stronger Context: The commercial imperative

Companies with products but problems with execution are always going to find themselves on the list of potential acquisition candidates. Such is the case with Transkaryotic Therapies Inc., as its pipeline now will be in the hands of a company that has reached its top tier valuation and cash flow on the back of company acquisitions in the U.S. and in-licensing of products in its targeted therapeutic areas, all under the umbrella of a commercially minded management.

TKTX's Gene Activation (GA) technology is based on a simple premise: produce proteins with known therapeutic efficacy in a novel way that doesn't infringe existing manufacturing processes. But the company's potentially biggest-selling product - Dynepo GA-EPO - has languished on the shelf for three years, stuck in the hands of a partner that had lost interest. ...